Change 5-day change 1-year change 3-year change Capi.($)
-9.09%-9.09% - - 30.31M
+0.31%-1.46%+2.77%+16.94% 49.74B
+2.09%-0.71%+452.73%+498.77% 44.98B
-1.09%-0.41%+35.40%+15.17% 42.52B
-0.26%-4.71%+17.19%+71.67% 40.78B
-0.48%-0.84%+16.25%+49.80% 32.89B
-1.06%+2.87% - - 17.09B
-1.81%-5.02%+22.65%+113.24% 16.28B
+0.20%-1.54%+16.78%+26.19% 14.4B
-2.05%-5.14%+72.89%+34.69% 13.48B
Average -1.53%-2.44%+79.58%+103.31% 30.24B
Weighted average by Cap. -0.48%-2.27%+97.37%+122.21%
Logo Ophthalix Inc
Wize Pharma Inc, formerly Ophthalix, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. The Company markets, sells and distributes a formula known as LO2A, which protects ocular surface tissues. LO2A is a drug developed for the treatment of DES and other ophthalmological illnesses, including conjunctivochalasis (CCH) and sjogren's syndrome (sjogren's).
Employees
-